{"transactions":[{"id":877520,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-27T21:52:39.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 26, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":1300000,"derivative":{"exercise_price":4.38,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0001628280-26-012893","document":"wk-form4_1772229156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026012893/wk-form4_1772229156.xml","form_type":"4"}},{"id":1074876,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:40.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":850000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":850000,"derivative":{"exercise_price":4.04,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001894562-25-000043","document":"wk-form4_1754440956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000043/wk-form4_1754440956.xml","form_type":"4"}},{"id":1074875,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:42:40.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":850000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.8,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001894562-25-000043","document":"wk-form4_1754440956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000043/wk-form4_1754440956.xml","form_type":"4"}},{"id":1137477,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-22T20:18:34.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":1.1772,"value":147150.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.20, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001894562-25-000026","document":"wk-form4_1747945107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000026/wk-form4_1747945107.xml","form_type":"4"}},{"id":1143110,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-19T23:44:15.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on May 19, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on May 19, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":2000000,"derivative":{"exercise_price":1.335,"underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001894562-25-000023","document":"wk-form4_1747698248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000023/wk-form4_1747698248.xml","form_type":"4"}},{"id":1152398,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-12T20:50:55.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 75,000 shares."}],"balance_after":850000,"derivative":{"exercise_price":6.8,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001894562-25-000020","document":"wk-form4_1747083048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000020/wk-form4_1747083048.xml","form_type":"4"}},{"id":1236171,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T01:11:12.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":275000,"derivative":{"exercise_price":2.42,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001894562-25-000002","document":"wk-form4_1741050667.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000002/wk-form4_1741050667.xml","form_type":"4"}},{"id":1339185,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-09T23:22:42.000Z","date":"2024-12-05","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 75,000 shares."}],"balance_after":775000,"derivative":{"exercise_price":6.8,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001894562-24-000047","document":"wk-form4_1733786555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456224000047/wk-form4_1733786555.xml","form_type":"4"}},{"id":1507355,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-21T20:11:34.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option initially granted to the Reporting Person on January 17, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 17, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares."}],"balance_after":100000,"derivative":{"exercise_price":6.8,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001894562-24-000024","document":"wk-form4_1716322282.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456224000024/wk-form4_1716322282.xml","form_type":"4"}},{"id":1675415,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-19T21:19:41.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on January 17, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":600000,"derivative":{"exercise_price":6.8,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001894562-24-000004","document":"wk-form4_1705699169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456224000004/wk-form4_1705699169.xml","form_type":"4"}},{"id":2041823,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T17:02:07.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":90000,"derivative":{"exercise_price":8.38,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001562180-23-000722","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714023/000156218023000722/primarydocument.xml","form_type":"4"}},{"id":2422140,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-28T16:26:47.000Z","date":"2022-01-26","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested."}],"balance_after":135000,"derivative":{"exercise_price":14.87,"expiration_date":"2032-01-25","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001562180-22-000748","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714023/000156218022000748/primarydocument.xml","form_type":"4"}},{"id":2606392,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2021-08-11T16:14:57.000Z","date":"2021-08-09","kind":"exercise","acquired":true,"shares":26892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the underlying shares of common stock on September 16, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested."}],"balance_after":257512,"derivative":{"exercise_price":3.72,"expiration_date":"2029-09-16","underlying":"Common Stock","underlying_shares":26892},"source":{"system":"sec-edgar","filing":"0001562180-21-005284","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714023/000156218021005284/primarydocument.xml","form_type":"4"}},{"id":2606391,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-11T16:14:57.000Z","date":"2021-08-09","kind":"exercise","acquired":true,"shares":26892,"price":3.72,"value":100038.24,"ownership":{"direct":true},"balance_after":53784,"source":{"system":"sec-edgar","filing":"0001562180-21-005284","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714023/000156218021005284/primarydocument.xml","form_type":"4"}},{"id":2888193,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T21:26:19.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 25% of the underlying shares of common stock on January 28, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested."}],"balance_after":120000,"derivative":{"exercise_price":16.63,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-21-003967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714023/000089924321003967/doc4.xml","form_type":"4"}},{"id":3625709,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-02-28T22:24:24.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter."}],"balance_after":162500,"derivative":{"exercise_price":3.09,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001562180-19-001487","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000156218019001487/primarydocument.xml","form_type":"4"}},{"id":4032984,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2018-02-27T00:15:55.000Z","date":"2018-02-20","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 9, 2017, the reporting person was granted an option to purchase up to a maximum of 50,000 shares of common stock of which 50,000 shares were earned based on the reporting person's achievement of his 2017 personal goals as certified by the Compensation Committee of the Board of Directors on February 20, 2018. The earned shares vest as to 25% on February 20, 2019 and the remainder vests as to an additional 6.25% quarterly thereafter beginning on the last day of the next calendar quarter."}],"balance_after":50000,"derivative":{"exercise_price":5,"expiration_date":"2027-08-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-18-001252","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000156218018001252/primarydocument.xml","form_type":"4"}},{"id":4032983,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2018-02-27T00:15:55.000Z","date":"2018-02-20","kind":"grant","acquired":true,"shares":53833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the option shares on January 1, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter."}],"balance_after":53833,"derivative":{"exercise_price":8.56,"expiration_date":"2028-02-20","underlying":"Common Stock","underlying_shares":53833},"source":{"system":"sec-edgar","filing":"0001562180-18-001252","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000156218018001252/primarydocument.xml","form_type":"4"}},{"id":4230242,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-08-17T23:19:50.000Z","date":"2017-08-17","kind":"purchase","acquired":true,"shares":20000,"price":4.89,"value":97800.0,"ownership":{"direct":true},"balance_after":65000,"source":{"system":"sec-edgar","filing":"0000899243-17-020635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000089924317020635/doc4.xml","form_type":"4"}},{"id":4230241,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-08-17T23:19:50.000Z","date":"2017-08-16","kind":"purchase","acquired":true,"shares":45000,"price":4.79,"value":215550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0000899243-17-020635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000089924317020635/doc4.xml","form_type":"4"}},{"id":4236250,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":64273,"kind":"person","name":"Reine Allan","position":1,"cik":"0001714023","reported_name":"Reine Allan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-08-12T01:20:02.000Z","date":"2017-08-09","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the option shares on August 9, 2018 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until August 9, 2021."}],"balance_after":450000,"derivative":{"exercise_price":5,"expiration_date":"2027-08-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-17-020179","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000089924317020179/doc4.xml","form_type":"4"}}]}